


In the claims:

1. (Currently Amended) An amide derivative represented by the following formula [1] in any of the following cases (A) or (B), or a salt thereof;




(A)

R¹ represents a saturated cyclic amino group (the saturated cyclic amino group may be substituted by 1 to 3 same or different members selected from the group consisting of alkyl, alkoxy carbonyl, halogen, haloalkyl, hydroxyalkyl, amino, monoalkylamino, dialkylamino, carbamoyl, monoalkylcarbamoyl and dialkylcarbamoyl), monoalkylamino or dialkylamino;

R² represents alkyl, halogen, haloalkyl, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxy carbonyl, acyl, amino, monoalkylamino, dialkylamino, nitro, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl or cyano;

R³ represents hydrogen, halogen or alkoxy;

Het1 represents any of groups of the following formulas [2] to [8];



Het2 represents pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl or 1, 2-dihydropyridazinyl (the Het2 may be substituted by 1 to 3 same or different members selected from the group consisting of alkyl, halogen and amino);

Excluding compound wherein R¹ is (i) pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl, all of which may be substituted by 1 to 3 same or different members selected from the group consisting of alkyl, alkoxy carbonyl, halogen, haloalkyl, hydroxylalkyl, amino, monoalkylamino, dialkylamino, carbamoyl, monoalkylcarbamoyl and dialkylcarbamoyl, (ii) monoalkylamino, or (iii) dialkylamino, Het1 is a group of the formula [6], and Het2 is pyrazinyl or pyridyl which may be substituted by alkyl;

(B)

R⁴ represents 4-methylpiperazin-1-yl, 1-pyrrolidinyl, piperidino, 4-ethylpiperazin-1-yl, 4-n-propylpiperazin-1-yl, cis-3, 5-dimethylpiperazin-1-yl, morpholino, dimethylamino or diethylamino;

R² represents methyl, halogen, trifluoromethyl, methoxy, methoxycarbonyl, nitro, dimethylcarbamoyl or cyano;

R³ represents hydrogen, bromo or methoxy;

Het1 represents a group of the formula [6], and

Het2 represents 3-pyridyl.

2. (Original) The amide derivative according to claim 1, or a salt thereof, wherein R¹ is a saturated cyclic amino group (the saturated cyclic amino group may be substituted by 1 to 3 same or different members selected from the group consisting of alkyl and alkoxy carbonyl), monoalkylamino or dialkylamino,

R² is alkyl, halogen, haloalkyl, alkoxy, alkoxy carbonyl, nitro, dialkylcarbamoyl or cyano,

R² is hydrogen, halogen or alkoxy,

Het1 is any of groups of the formulas [2] to [8], and

Het2 is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl or 1, 2-dihydropyridazinyl (the Het2 may be substituted by 1 to 3 same or different halogen).

3. (Currently Amended) The amide derivative according to claim 1, which is a compound selected from the group consisting of the following compounds (1) to (40 18), or a salt thereof:

(1) — 3-bromo 4-(4-methylpiperazin-1-ylmethyl)-N-(4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl)benzamide

(2) — 3-iodo 4-(4-methylpiperazin-1-ylmethyl)-N-(4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl)benzamide;

(3) — 3-chloro 4-(4-methylpiperazin-1-ylmethyl)-N-(4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl)benzamide;

(4) — 3-fluoro 4-(4-methylpiperazin-1-ylmethyl)-N-(4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl)benzamide,

- (5) 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-(4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino] phenyl} benzamide,
- (6 1) 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl) pyrimidin-2-ylamino] phenyl}benzamide,
- (7) 3-bromo 4-(4-methylpiperazin-1-ylmethyl)-N-(4-methyl-3-[4-(2-pyrazinyl) pyrimidin-2-ylamino] phenyl}benzamide,
- (8 2) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{3-[4-(6-chloropyridin-3-yl) pyrimidin-2-ylamino] -4-methylphenyl } benzamide,
- (9 3) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{3-[4-(5-bromopyridin-3-yl) pyrimidin-2-ylamino] -4-methylphenyl} benzamide,
- (10 4) 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{3-[4-(5-bromopyridin-3-yl)pyrimidin-2-ylamino]-4-methylphenyl } benzamide,
- (11 5) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{3-[4-(1, 2-dihydropyridazin-4-yl) pyrimidin-2-ylamino] -4-methylphenyl } benzamide,
- (12 6) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridazinyl) pyrimidin-2-ylamino] phenyl }benzamide,
- (13 7) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl) pyrimidin-2-ylamino] phenyl } benzamide,
- (14 8) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl) pyridin-2-ylamino] phenyl } benzamide.
- (15 9) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl) pyridin-2-ylamino] phenyl}benzamide.

(46 10) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[2-(3-pyridyl) pyridin-6-ylamino] phenyl}benzamide,

(47 11) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[3-(3-pyridyl) pyridin-5-ylamino] phenyl}benzamide,

(48 12) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[3 -(3 -pyridyl) phenylamino] phenyl } benzamide,

(49 13) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[2-(3-pyridyl) pyrazin-6-ylamino] phenyl}benzamide,

(50 14) 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[5 -(3 -pyridyl)-1, 2, 4-triazin-3-ylamino] phenyl}benzamide,

(21) — 3-methyl-4-(4-methylpiperazin-1-ylmethyl)-N-(4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl)benzamide;

(22) — 4-(4-methylpiperazin-1-ylmethyl)-3-nitro-N-(4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl)benzamide;

(23) — 3-methoxy-4-(4-methylpiperazin-1-ylmethyl)-N-(4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl)benzamide;

(24) — 3, 5-dibromo-4-(4-methylpiperazin-1-ylmethyl)-N-(4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl)benzamide;

(25) — 3, 5-dimethoxy-4-(4-methylpiperazin-1-ylmethyl)-N-(4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl)benzamide;

(26) — 3-(N,N-dimethylcarbamoyl)-4-(4-methylpiperazin-1-ylmethyl)-N-(4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino] phenyl)benzamide;

- (27) 3-bromo-4-(4-ethylpiperazin-1-ylmethyl)-N-(4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl)benzamide;
- (28) 3-bromo-4-[4-(n-propyl)piperazin-1-ylmethyl]-N-(4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl)benzamide;
- (29) 3-bromo-4-(N,N-dimethylaminomethyl)-N-(4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl)benzamide;
- (30) 3-bromo-4-(N,N-diethylaminomethyl)-N-(4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl)benzamide;
- (31) 3-bromo-4-(1-pyrrolidinylmethyl)-N-(4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl)benzamide;
- (32) 3-bromo-4-(piperidinomethyl)-N-(4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl)benzamide;
- (33) 3-bromo-4-(morpholinomethyl)-N-(4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl)benzamide;
- (34) 3-bromo-4-(cis-3,5-dimethylpiperazin-1-ylmethyl)-N-(4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl)benzamide;
- (35) 3-bromo-4-(4-methyl-hexahydro-1H-1,4-diazepin-1-ylmethyl)-N-(4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl)benzamide,
- (36) 3-bromo-4-(1-piperazinylmethyl)-N-(4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl)benzamide,
- (37) 4-[4-(t-butoxycarbonyl)piperazin-1-ylmethyl]-3-trifluoromethyl-N-(4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl)benzamide, and

- (38) 18) 4-(1-piperazinylmethyl)-3-trifluoromethyl-N-[4-methyl-3-[4-(5-pyrimidinyl) pyrimidin-2-ylamino]phenyl } benzamide₅₂
- (39) — 3 methoxycarbonyl 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino]phenyl]benzamide, and
- (40) — 3 cyano 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[4-(3-pyridyl) pyrimidin-2-ylamino]phenyl]benzamide.

4. (Previously Presented) A pharmaceutical composition comprising the amide derivative of claim 1 or a salt thereof as an active ingredient and a pharmaceutically acceptable carrier.

5. - 8. (Cancelled)

9. (Previously Presented) A method of treating a subject having acute lymphoblastic leukemia comprising administering to the subject an effective amount of the amide derivative of claim 1 or a salt thereof.

10. (Previously Presented) A method of treating a subject having acute myelogenous leukemia comprising administering to the subject an effective amount of the amide derivative of claim 1 or a salt thereof.

11. (Previously Presented) A method of treating a subject having acute myelogenous leukemia comprising administering to the subject an effective amount of the amide derivative of claim 1 or a salt thereof.